Navigation Links
Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data
Date:4/17/2008

a Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effe
'/>"/>

SOURCE Arpida
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
5. New knock-out gene model provides molecular clues to breast cancer
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. SIV infection of natural hosts provides new insights into HIV disease complexity
8. Microarray provides 3 genomic guides to breast cancer treatment decisions
9. Access Innovations Provides Support Services for Agis Network
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Physical Therapist Provides Injury Analysis for Fantasy Football
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... ... - Gross margin expanded to 32.4 percent from ... Health management segment revenue grew 25 percent, - Net earnings: ... Nov. 3 Health Fitness,Corporation (NYSE Alternext US: FIT), a leading provider ...
... Held on Thursday November 6 at 8:30,a.m., NEW ... Board: VION) today announced financial,results for the three-month and ... a net loss of $6.8 million, or $0.92 per ... to a net loss,of $9.0 million, or $1.33 per ...
... neck, government study finds , , MONDAY, Nov. 3 (HealthDay ... with human papillomavirus (HPV) occurred in 38 states and ... officials reported Monday. , HPV is a group of ... than 30 of which can be sexually transmitted. Most ...
... A recent study conducted by researchers at Georgia ... demonstrate that administration of preemptive morphine prior to a ... of pain in adult rodents. These studies have ... administered to neonates prior to surgery. Infant rodents that ...
... Center at the University of California, San Diego (UCSD) ... at revving up the immune system to combat a ... therapy is being offered to patients with chronic lymphocytic ... resistant to initial treatment or harbors a particular chromosomal ...
... Revenue for the third quarter 2008 increases 32% to $16.0 million. - Heart ... surgical ablation products revenue grows 21.7%. ... Company raises lower end of its 2008 revenue guidance to $65 - $66 ... ...
Cached Medicine News:Health News:HealthFitness Announces 2008 Third Quarter Results 2Health News:HealthFitness Announces 2008 Third Quarter Results 3Health News:HealthFitness Announces 2008 Third Quarter Results 4Health News:HealthFitness Announces 2008 Third Quarter Results 5Health News:HealthFitness Announces 2008 Third Quarter Results 6Health News:HealthFitness Announces 2008 Third Quarter Results 7Health News:HealthFitness Announces 2008 Third Quarter Results 8Health News:HealthFitness Announces 2008 Third Quarter Results 9Health News:HealthFitness Announces 2008 Third Quarter Results 10Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 2Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 3Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 4Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 5Health News:U.S. Reported 25,000 Cases of HPV-Related Cancers Annually 2Health News:GSU study first to confirm long-term benefits of morphine treatment in infants 2Health News:Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients 2Health News:ATS Medical Announces Third Quarter Results 2Health News:ATS Medical Announces Third Quarter Results 3Health News:ATS Medical Announces Third Quarter Results 4Health News:ATS Medical Announces Third Quarter Results 5Health News:ATS Medical Announces Third Quarter Results 6Health News:ATS Medical Announces Third Quarter Results 7Health News:ATS Medical Announces Third Quarter Results 8
(Date:1/14/2014)... Critical Care, a LifeCentre partner practice, located at 165 Fort Evans ... in Loudoun County to receive a small ... Barnes , Medical Director, is a well-seasoned veterinarian of more than ... are avid scuba divers. "As altitude skiers and hikers, we recognize ...
(Date:1/14/2014)... Jan. 14, 2014 NineSigma , Inc., the ... Innovation Leadership Summit , May 14-16, 2014 at ... Cleveland Ohio . This is ... committed to breakthrough achievements through open innovation. Participants will ...
(Date:1/14/2014)... New York , January 14, 2014 ... Closed System Transfer Devices (CSTD) for hazardous drugs, today announced ... for the fourth straight year.   ... for pharmacy technicians, pharmacists, nurses and other medical ...
Breaking Medicine Technology:Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
... L-XP ultracentrifuge is designed to play ... process if research involves proteomics, cytomics ... on-board computer, enhanced firmware, powerful Optima ... screen, Optima L-XP delivers superior functionality, ...
... small-volume samples. With the ability to provide ... (fat particles in lipemic samples), the Airfuge ... Lipemic samples can be cleaned in 10 ... The easy-to-operate tabletop centrifuge: Reaches top speed ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
Medicine Products: